Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. September 2025 07:00 ET | Quelle: Cancer Focus Fund

Cancer Focus Fund Appoints Distinguished Industry Experts David R. Epstein and Michael Margolis as Advisors to Its Investment Committee

Industry veterans David R. Epstein and Michael A. Margolis have been appointed as members of Cancer Focus Fund's Investment Committee Advisory Board.
01. Mai 2025 08:00 ET | Quelle: Cancer Focus Fund; ImmunoGenesis

ImmunoGenesis Expands Phase 1a/b Trial of IMGS-001 for Advanced Solid Tumors to Ochsner MD Anderson Cancer Center

The Phase 1 trial of IMGS-001-a novel dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function-is expanding to Ochsner MD Anderson Cancer Center.
23. Oktober 2024 07:00 ET | Quelle: Cancer Focus Fund; Starget Pharma

Starget Pharma and Cancer Focus Fund Announce $5.1 Million Investment to Support Phase 1b Clinical Trial of Novel Peptide Radioligand for Precision Cancer Therapy

Cancer Focus Fund invested $5.1M in precision peptide radioligand developer Starget for a Phase 1b trial at MD Anderson of its lead theranostic DOTA-PTR-58
21. März 2024 07:00 ET | Quelle: Cancer Focus Fund; Eisbach Bio GmbH

Eisbach and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumors

Cancer Focus Fund is investing $4.5M for clinical trial of Eisbach's novel approach using synthetic lethality to kill PARP inhibitor resistant tumors